Prothena (PRTA) said late Friday that it will discontinue the development of birtamimab after the phase 3 Affirm-Al trial of monoclonal antibody failed to meet the primary endpoint in treating patients with AL amyloidosis, or amyloid light chain amyloidosis.
The company said it will also stop the open-label extension of the Affirm-Al clinical trial.
Prothena said it expects to provide details of its plans to reduce ongoing operating expenses, which include job cuts, in June and the results of its review of business options once finalized.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。